Chemiderm cream

Chemiderm

  • Active Ingredient: Terbinafine
  • 250 mg
Buy Now

What is Chemiderm?

The active ingredient of Chemiderm brand is terbinafine. Terbinafine is an antifungal medication that fights infections caused by fungus. Terbinafine hydrochloride USP is a white to off-white fine crystalline powder. It is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water. Each tablet contains: Active Ingredient: Terbinafine hydrochloride USP (equivalent to 250 mg of Terbinafine) Inactive Ingredients: Microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, hypromellose, and magnesium stearate.

Used for

Chemiderm is used to treat diseases such as: Cutaneous Candidiasis, Onychomycosis, Fingernail, Onychomycosis, Toenail, Tinea Capitis, Tinea Corporis, Tinea Cruris, Tinea Pedis.

Side Effect

Possible side effects of Chemiderm include: ear congestion; red skin lesions, often with a purple center; change of taste or loss of taste; nasal congestion; diarrhea.

How to Buy Chemiderm tablets online?

To purchase Chemiderm online - just click on the "Buy Now" button in the top and follow along with our store. Payment and Order takes a couple of minutes, and all measures are evident. We don't require a medical prescription and we have many methods of payment. With all the details of rapid shipping and confidentiality, you may read on the applicable pages on the links from the top menu.

Related Medications

Fungueal

Fungueal 250mg

terbinafine

More info

Figalol

Figalol 200mg, 150mg, 50mg

fluconazole

More info

Fungo

Fungo 200mg, 150mg, 50mg

fluconazole

More info

Enschent

Enschent 10mg

clotrimazole

More info

Contraindications

Chemiderm tablets are contraindicated in patients with:

  • Chronic ‚Äč or active liver disease
  • History of allergic reaction to oral Chemiderm because of the risk of anaphylaxis

Postmarketing Experience

The following adverse events have been identified during postapproval use of Lamisil Tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune system disorders: Serious hypersensitivity reactions e.g., angioedema and allergic reactions (including anaphylaxis), precipitation and exacerbation of cutaneous and systemic lupus erythematosus , serum sickness-like reaction

Psychiatric disorders: Anxiety and depressive symptoms independent of taste disturbance have been reported with use of Lamisil Tablets. In some cases, depressive symptoms have been reported to subside with discontinuance of therapy and to recur with reinstitution of therapy .

Nervous system disorders: Cases of taste disturbance, including taste loss, have been reported with the use of Lamisil Tablets. It can be severe enough to result in decreased food intake, weight loss, anxiety, and depressive symptoms. Cases of smell disturbance, including smell loss, have been reported with the use of Lamisil Tablets . Cases of paresthesia and hypoesthesia have been reported with the use of Lamisil Tablets.

Ear and labyrinth disorders: Hearing impairment, vertigo, tinnitus

Hepatobiliary disorders: Cases of liver failure some leading to liver transplant or death , idiosyncratic and symptomatic hepatic injury. Cases of hepatitis, cholestasis, and increased hepatic enzymes have been seen with the use of Lamisil Tablets.

Skin and subcutaneous tissue disorders: Serious skin reactions , acute generalized exanthematous pustulosis, psoriasiform eruptions or exacerbation of psoriasis, photosensitivity reactions, hair loss

Musculoskeletal and connective tissue disorders: Rhabdomyolysis, arthralgia, myalgia

General disorders and administration site conditions: Malaise, fatigue, influenza-like illness, pyrexia

Investigations: Altered prothrombin time (prolongation and reduction) in patients concomitantly treated with warfarin and increased blood creatine phosphokinase have been reported

Read the entire FDA prescribing information for Lamisil (Chemiderm)

What should I discuss with my healthcare prov >

You should not use Chemiderm if you are allergic to it, or if you have:

  • liver disease.

To make sure Chemiderm is safe for you, tell your doctor if you have ever had:

  • liver problems;
  • weak immune system (caused by disease or by using certain medicine); or
  • lupus.

It is not known whether this medicine will harm an unborn baby. You should wait until after your pregnancy to start treating your nail or scalp infection with Chemiderm. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

Chemiderm can pass into breast milk and may harm a nursing baby. You should not breast-feed while using this medicine.

Postmarketing Experience

The following adverse events have been identified during post-approval use of Chemiderm tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Pancytopenia, agranulocytosis, severe neutropenia, thrombocytopenia, anemia, thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome Immune system disorders: Serious hypersensitivity reactions e.g., angioedema and allergic reactions (including anaphylaxis), precipitation and exacerbation of cutaneous and systemic lupus erythematosus , serum sickness-like reaction

Psychiatric disorders: Anxiety and depressive symptoms independent of taste disturbance have been reported with use of Chemiderm tablets. In some cases, depressive symptoms have been reported to subs >. Nervous system disorders: Cases of taste disturbance, including taste loss, have been reported with the use of Chemiderm tablets. It can be severe enough to result in decreased food intake, weight loss, anxiety, and depressive symptoms. Cases of smell disturbance, including smell loss, have been reported with the use of Chemiderm tablets . Cases of paresthesia and hypoesthesia have been reported with the use of Chemiderm tablets.

Eye disorders: Visual field defects, reduced visual acuity Ear and labyrinth disorders: Hearing impairment, vertigo, tinnitus Vascular disorders: Vasculitis Gastrointestinal disorders: Pancreatitis, vomiting Hepatobiliary disorders: Cases of liver failure some leading to liver transplant or death , > have been seen with the use of Chemiderm tablets. Skin and subcutaneous tissue disorders: Serious skin reactions , acute generalized exanthematous pustulosis, psoriasiform eruptions or exacerbation of psoriasis, photosensitivity reactions, hair loss Musculoskeletal and connective tissue disorders: Rhabdomyolysis, arthralgia, myalgia General disorders and administration site conditions: Malaise, fatigue, influenza-like illness, pyrexia Investigations: Altered prothrombin time (prolongation and reduction) in patients concomitantly treated with warfarin and increased blood creatine phosphokinase have been reported

Clinical applications

Chemiderm has been most extensively studied for the treatment of dermatophytes. There are few clinical studies of Chemiderm use in veterinary patients with other fungal infections. In the cat the drug shows great promise in the treatment of dermatophytes. In humans the drug is most extensively used in the treatment of onychomycosis, dermatophytosis and tinea infections. Pharmacoeconomically, it is considered the drug of choice for treating dermatophyte infections in humans. It also has shown good efficacy when used to treat sporotrichosis. Systemic mycoses are typically less responsive than the superficial mycoses.

Chemiderm is sometimes combined with itraconazole for the treatment of mycotic infections that are traditionally difficult to treat medically, such as pheohyphomycosis, hyalohyphomycosis, systemic aspergillosis, pythiosis and lagenidiosis.

For the treatment of Raynaud's Syndrome order Beglaryl no prescription tablets Blood Pressure

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because treatment of onychomycosis can be postponed until after pregnancy is completed, it is recommended that Lamisil Tablets not be initiated during pregnancy.

Oral reproduction studies have been performed in rabbits and rats at doses up to 300 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to Chemiderm.

Pediatric Use

The safety and efficacy of Chemiderm tablets have not been established in pediatric patients with onychomycosis.

What is the most important information I should know about Chemiderm (LamISIL)?

Some people taking Chemiderm have developed severe liver damage leading to liver transplant or death.

Call your doctor at once if you have symptoms of liver damage, such as nausea, upper stomach pain, vomiting, loss of appetite, tiredness, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes). These events can occur whether or not you have ever had liver problems before.

QUESTION

OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Do not share this medication with others.This medication has been prescribed for your current condition only. Do not use it later for another infection unless your doctor directs you to do so. A different medication may be necessary in those cases.Laboratory and/or medical tests (e.g., complete blood counts, liver function tests) should be performed before you start Chemiderm and periodically during your treatment to check for side effects. Consult your doctor for more details.

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store at room temperature at 77 degrees F (25 degrees C) away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Information last revised June 2013. Copyright(c) 2013 First Databank, Inc.

What is the metabolism of Chemiderm?

Chemiderm is absorbed well when taken orally, with or without food. It is bound to proteins such as albumin in the circulating blood and becomes concentrated in fat cells and within skin and nails . It is slowly eliminated in faeces and urine mostly after conversion by the liver into inactive compounds. It is a moderate CYP2D6 inhibitor. Doses may need to be reduced in the presence of kidney disease.

Skin concentrations may be up to 75-fold higher than those in the blood. It may persist in the skin for up to 8 weeks after the drug has been discontinued and in the nails for up to a year.

Other uses for this medicine

Chemiderm is also sometimes used to treat ringworm (fungal infections of the skin that cause a red scaly rash on different parts of the body) and jock itch (fungal infection of the skin in the groin or buttocks). Talk to your doctor about the risks of using this medication for your condition.

Animal Toxicology and/or Pharmacology

A w >in vivo studies in mice, rats, dogs, and monkeys, and in vitro studies using rat, monkey, and human hepatocytes suggest that peroxisome proliferation in the liver is a rat-specific finding. However, other effects, including increased liver weights and APTT, occurred in dogs and monkeys at doses giving C ss trough levels of the parent Chemiderm 2 to 3 times those seen in humans at the MRHD. In a 52-week oral toxicology study conducted in juvenile maturing dogs, increased heart and liver weights were noted in males and signs of CNS disturbance including 3 cases of single episodes of seizures were noted in females at the highest dose tested, 100 mg/kg/day . No treatment related findings were noted at 30 mg/kg/day in this study.


© Copyright 2017-2020 - rootsdentclinic.com - We Care About You!

Sitemap